학술논문

A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer
Document Type
Journal
Source
CANCER RESEARCH; FEB 15 2022, 82 4, 3p. Supplement: S
Subject
Language
English
ISSN
15387445